Success Metrics

Clinical Success Rate
89.4%

Based on 84 completed trials

Completion Rate
89%(84/94)
Active Trials
3(3%)
Results Posted
68%(57 trials)
Terminated
10(10%)

Phase Distribution

Ph not_applicable
5
5%
Ph early_phase_1
1
1%
Ph phase_4
27
26%
Ph phase_3
27
26%
Ph phase_1
14
13%
Ph phase_2
24
23%

Phase Distribution

15

Early Stage

24

Mid Stage

54

Late Stage

Phase Distribution98 total trials
Early Phase 1First-in-human
1(1.0%)
Phase 1Safety & dosage
14(14.3%)
Phase 2Efficacy & side effects
24(24.5%)
Phase 3Large-scale testing
27(27.6%)
Phase 4Post-market surveillance
27(27.6%)
N/ANon-phased studies
5(5.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.8%

84 of 99 finished

Non-Completion Rate

15.2%

15 ended early

Currently Active

3

trials recruiting

Total Trials

104

all time

Status Distribution
Active(4)
Completed(84)
Terminated(15)
Other(1)

Detailed Status

Completed84
Terminated10
Withdrawn5
Active, not recruiting3
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
104
Active
3
Success Rate
89.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.0%)
Phase 114 (14.3%)
Phase 224 (24.5%)
Phase 327 (27.6%)
Phase 427 (27.6%)
N/A5 (5.1%)

Trials by Status

active_not_recruiting33%
not_yet_recruiting11%
terminated1010%
completed8481%
unknown11%
withdrawn55%

Recent Activity

Clinical Trials (104)

Showing 20 of 104 trialsScroll for more
NCT07664527Phase 4

Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate

Not Yet Recruiting
NCT05535738Phase 2

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Active Not Recruiting
NCT02476825Phase 4

A Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids on Adult Healthy Volunteers

Active Not Recruiting
NCT01396278Phase 2

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

Terminated
NCT03040596Phase 1

The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children

Terminated
NCT05444543Phase 4

Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)

Completed
NCT02402465Phase 4

Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis

Completed
NCT03199976Phase 4

Efficacy of Intermittent Tiotropium in Early Childhood Wheezing

Terminated
NCT00127166Phase 3

Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)

Completed
NCT04601324Phase 4

Allergic Rhinitis Combination Pharmacotherapy Efficacy Study

Withdrawn
NCT03926026Phase 2

Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis

Completed
NCT02246920Phase 3

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

Terminated
NCT00995475Phase 4

A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease

Completed
NCT04171167Not Applicable

The Causal Relation of Nasal Nitric Oxide Levels to the Severity of Chronic Rhinosinusitis and Its Inflammatory Phenotype

Active Not Recruiting
NCT05314621Phase 4

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis

Completed
NCT01397162Phase 2

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

Terminated
NCT01397201Phase 2

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

Terminated
NCT02232087Phase 1

Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate

Completed
NCT01092143Phase 2

BI 671800 ED in Steroid-naive Asthmatic Patients

Completed
NCT00540839Phase 3

A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
104